Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov;116(3):139-45.
doi: 10.1016/j.ymgme.2015.08.011. Epub 2015 Sep 2.

Recurrent ACADVL molecular findings in individuals with a positive newborn screen for very long chain acyl-coA dehydrogenase (VLCAD) deficiency in the United States

Marcus J Miller  1 , Lindsay C Burrage  1 , James B Gibson  2 , Meghan E Strenk  3 , Edward J Lose  4 , David P Bick  5 , Sarah H Elsea  1 , V Reid Sutton  1 , Qin Sun  1 , Brett H Graham  1 , William J Craigen  1 , Victor Wei Zhang  1 , Lee-Jun C Wong  6
Affiliations

Recurrent ACADVL molecular findings in individuals with a positive newborn screen for very long chain acyl-coA dehydrogenase (VLCAD) deficiency in the United States

Marcus J Miller et al. Mol Genet Metab. 2015 Nov.

Abstract

Very long chain acyl-coA dehydrogenase deficiency (VLCADD) is an autosomal recessive inborn error of fatty acid oxidation detected by newborn screening (NBS). Follow-up molecular analyses are often required to clarify VLCADD-suggestive NBS results, but to date the outcome of these studies are not well described for the general screen-positive population. In the following study, we report the molecular findings for 693 unrelated patients that sequentially received Sanger sequence analysis of ACADVL as a result of a positive NBS for VLCADD. Highlighting the variable molecular underpinnings of this disorder, we identified 94 different pathogenic ACADVL variants (40 novel), as well as 134 variants of unknown clinical significance (VUSs). Evidence for the pathogenicity of a subset of recurrent VUSs was provided using multiple in silico analyses. Surprisingly, the most frequent finding in our cohort was carrier status, 57% all individuals had a single pathogenic variant or VUS. This result was further supported by follow-up array and/or acylcarnitine analysis that failed to provide evidence of a second pathogenic allele. Notably, exon-targeted array analysis of 131 individuals screen positive for VLCADD failed to identify copy number changes in ACADVL thus suggesting this test has a low yield in the setting of NBS follow-up. While no genotype was common, the c.848T>C (p.V283A) pathogenic variant was clearly the most frequent; at least one copy was found in ~10% of all individuals with a positive NBS. Clinical and biochemical data for seven unrelated patients homozygous for the p.V283A allele suggests that it results in a mild phenotype that responds well to standard treatment, but hypoglycemia can occur. Collectively, our data illustrate the molecular heterogeneity of VLCADD and provide novel insight into the outcomes of NBS for this disorder.

Keywords: ACADVL; Fatty acid oxidation; Inborn error of metabolism; NBS; Newborn screening; V243A; V283A; VLCAD; VLCADD.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: All authors declare that there is no conflict of interest. Dr.'s Elsea, Sutton, Sun, Craigen, Zhang, and Wong are faculty in the department of Molecular and Human Genetics at the Baylor College of Medicine (BCM) and also directors within the Medical Genetics Laboratories (MGL). The MGL is jointly owned by BCM and Miraca Life Sciences and provides a number of clinical tests on a fee-for-service basis including those described in this manuscript.

Figures

Fig. 1
Fig. 1
The flowchart describes the samples sent to our laboratory for Sanger sequence analysis of ACADVL over the course of seven years. Grey boxes indicate samples analyzed in this study. pNBS= presumptive newborn screen positive.
Fig. 2
Fig. 2. Pathogenic variants detected in patients soliciting molecular analysis after a postive NBS suggestive of VLCADD
All pathogenic variants detected in our NBS or pNBS cohort are listed. The font size is proportional to the allele frequency. Novel pathogenic variants are shown in red. Black boxes indicate exons and grey lines indicate introns of ACADVL.
Fig. 3
Fig. 3. Structural analysis of VLCAD variants
Enriched VUSs, described in Table 1, were plotted on the crystal structure of the VLCAD homodimer (PDB# 2UXW) where the two VLCAD moieties are indicated by yellow and blue ribbon structures. Red spheres indicate the location of VUSs. Stick diagrams indicate the location of the substrate (Palmitoyl-CoA) and the cofactor, flavin adenine dinucleotide (FAD). The location of the catalytic residue, Glu462, and the p.V283A pathogenic variant are shown by green spheres.
Fig. 4
Fig. 4. Follow-up quantitative plasma acylcarnitine data for patients with a positive NBS suggestive of VLCADD
(A) Plasma C14:1 levels from the first quantitative plasma acylcarnitine analysis following a positive NBS are plotted in relation to the patient's molecular finding. For example, red dots indicate C14.1 values for patients harboring two pathogenic variants and blue dots indicate C14.1 values for patients with no variants in ACADVL. The number of unique patients in each genotypic class is shown (n) and specific genotypes are listed for a few notable cases- indicated by numbers. The asterisk indicates findings for case PAT0165 that is further explored in Fig. 2B. (B) Plasma C14:1 levels are shown for seven different follow-up analyses completed over the course of 3 years for PAT0165. Grey dotted lines indicate the upper limit of normal (95th percentile for unaffected individuals tested in our laboratory).
Fig. 5
Fig. 5. Quantitative plasma acylcarnitine analysis in patients homozygous for the p.V283A allele
All available plasma C14:1 test results are shown in relation to the patient's age at sampling. Presumably many of these tests were completed when the patient was receiving treatment for VLCADD. The dotted grey line is representative of the normal range of plasma C14:1 levels in unaffected individuals.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aoyama T, Souri M, Ueno I, Kamijo T, Yamaguchi S, Rhead WJ, Tanaka K, Hashimoto T. Cloning of human very-long-chain acyl-coenzyme A dehydrogenase and molecular characterization of its deficiency in two patients. Am J Hum Genet. 1995;57:273–283. - PMC - PubMed
    1. Strauss AW, Powell CK, Hale DE, Anderson MM, Ahuja A, Brackett JC, Sims HF. Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. Proc Natl Acad Sci U S A. 1995;92:10496–10500. - PMC - PubMed
    1. Hale DE, Batshaw ML, Coates PM, Frerman FE, Goodman SI, Singh I, Stanley CA. Long-chain acyl coenzyme A dehydrogenase deficiency: an inherited cause of nonketotic hypoglycemia. Pediatr Res. 1985;19:666–671. - PubMed
    1. Wilcken B. Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis. 2010;33:501–506. - PubMed
    1. Spiekerkoetter U, Lindner M, Santer R, Grotzke M, Baumgartner MR, Boehles H, Das A, Haase C, Hennermann JB, Karall D, de Klerk H, Knerr I, Koch HG, Plecko B, Roschinger W, Schwab KO, Scheible D, Wijburg FA, Zschocke J, Mayatepek E, Wendel U. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J Inherit Metab Dis. 2009;32:488–497. - PubMed

Publication types

MeSH terms

Supplementary concepts